Trials / Recruiting
RecruitingNCT06257680
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
A Single-armed, Open, Phase I Study of ReT01 ACT Injection in the Treatment of Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Aeonvital Biomedicine · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ReT01 ACT | Patients were infused with ReT01 ACT injection after pretreatment, and subjects were closely observed for 24 hours after each infusion. |
Timeline
- Start date
- 2024-04-08
- Primary completion
- 2025-02-18
- Completion
- 2027-02-18
- First posted
- 2024-02-14
- Last updated
- 2024-07-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06257680. Inclusion in this directory is not an endorsement.